semaglutide type 1 diabetes randomized trial 2024 A drug. Then a weight-loss drug. Then a global blockbuster. Here's how GLP-1s went from helping manage blood sugar to becoming one of medicine's biggest stories. [GLP-1, Ozempic, Wegovy, Mounjaro, diabetes Efficacy and Safety of Once-Weekly

The higher the dosage, the more aggressive it is in blocking the melanin-production process

The medication is being prescribed to reduce excess body weight or maintain weight reduction

Analysts predict peak sales of approximately $2 billion by 2030 if successful

Ozempic Class-Action Lawsuit Accordingly, in February 2024, The U.S

Retatrutide Regulatory Status Retatrutide occupies a unique position because it is not yet FDA-approved: Not FDA-approved currently in Phase 3 clinical trials with Eli Lilly No prescription pathway in the US yet no Mounjaro/Wegovy equivalent for retatrutide Legal as research chemical sold in the US for in-vitro and animal research under research-use-only labeling Likely to receive FDA approval in coming years if clinical trial endpoints meet expectations WADA status currently not specifically listed, though peptide hormones generally fall under WADA categories Not DEA-scheduled no controlled substance status Unlike semaglutide and tirzepatide, retatrutide does not yet exist as a prescription drug